Share

January 07, 2014; 82 (1) Editorial

BCG vaccine for clinically isolated syndrome and MS

Infections and protective immunity

Dennis Bourdette, Robert T. Naismith
First published December 4, 2013, DOI: https://doi.org/10.1212/01.wnl.0000438232.40847.c3
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
392

Share

Article Information

vol. 82 no. 1 15-16
DOI: 
https://doi.org/10.1212/01.wnl.0000438232.40847.c3
PubMed: 
24306000
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published December 4, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Dennis Bourdette, MD, FAAN, FANA and
    2. Robert T. Naismith, MD
  1. Dennis Bourdette, MD, FAAN, FANA and
    2. Scientific Advisory Boards:

    1. I serve on a scientific advisory board for the non-profit entity NYSTEM

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I have received honoraria for speaking from Biogen Idec, Teva Neurosciences and Genzyme.

    Editorial Boards:

    1. Journal of Medicinal Medicine, Associate Editor, 2009-present ; Current Neurology and Neuroscience Reports, Section Editor, 2008-present; Autoimmune Diseases, Associate Editor, 2009-present; Neurology, Member Editorial Board, 2013-present present. I receive no compensation for any of these activities.

    Patents:

    1. I have a use patent pending for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have served as a consultant to Teva Neurosciences and Biogen Idec in the past 12 months.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. I have received support for patient and physician education programs from Teva Neuroscience, Biogen Idec, EMD Serono, Accorda and Novartis.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1. Department of Veterans Affairs/BLR&D, Merit Review, PI, 10/1/09-9/30/13 2. Department of Veterans Affairs/Rehabilitation R&D, Merit Review, 1/1/12-12/31/15

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Use patent pending for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin, royalty payment from DebioPharma in 2012 and 2013.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Robert T. Naismith, MD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1) Acorda Therapeutics, speaker honoraria and travel (commercial) 2) Bayer Healthcare, speaker honoraria and travel (commercial) 3) Biogen IDEC, speaker honoraria and travel (commercial) 4) Genzyme Corporation, speaker honoraria and travel (commercial) 5) National MS Society, speaker honoraria and travel (not-for profit) 6) Consortium MS Centers, speaker honoraria and travel (not-for-profit) 7) EMD Serono, consulting honoraria and travel (commercial) 8) Questcor Therapeutics, consulting honoraria and travel (commercial)

    Editorial Boards:

    1. Journal Watch 2010-present, Associate Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. 1) Acorda Therapeutics (commercial) 2) Bayer Healthcare (commercial) 3) Biogen Idec (commercial) 4) Genzyme Corporation (commercial)

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Acorda Therapeutics - Washington University site PI for national Fampridine SR clinical trial, 2004-2010. Dalfampridine for vision after optic neuritis in MS, 2011-present.

    Research Support, Government Entities:

    1. NIH funding included K23NS052430-01A1

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (D.B.), Oregon Health & Science University and Multiple Sclerosis Centers of Excellence-West, Veterans Affairs Medical Center, Portland; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO.
  1. Correspondence to Dr. Bourdette: bourdett{at}ohsu.edu
View Full Text

Article usage

Article usage: December 2013 to July 2022

AbstractFullPdfSource
Dec 2013155915160Highwire
Jan 20146226785Highwire
Feb 20142371928Highwire
Mar 2014192914Highwire
Apr 201414023Highwire
May 201410924Highwire
Jun 201491810Highwire
Jul 20147216Highwire
Aug 20145823Highwire
Sep 20148364Highwire
Oct 20147930Highwire
Nov 20148513Highwire
Dec 20148714Highwire
Jan 20157722Highwire
Feb 20155300Highwire
Mar 20156524Highwire
Apr 20153741Highwire
May 20156000Highwire
Jun 20158136Highwire
Jul 20158500Highwire
Aug 20158200Highwire
Sep 20158211Highwire
Oct 20156200Highwire
Nov 20153634Highwire
Dec 20154420Highwire
Jan 20164000Highwire
Feb 20162400Highwire
Mar 20163813Highwire
Apr 20163513Highwire
May 20163200Highwire
Jun 20164900Highwire
Jul 20163610Highwire
Aug 20163100Highwire
Sep 20164910Highwire
Oct 20164101Highwire
Nov 20167004Highwire
Dec 20165701Highwire
Jan 20179101Highwire
Feb 20176910Highwire
Mar 20175700Highwire
Apr 20175811Highwire
May 20173200Highwire
Jun 20174243Highwire
Jul 20174313Highwire
Aug 20173223Highwire
Sep 20173111Highwire
Oct 20172600Highwire
Nov 20173321Highwire
Dec 20172900Highwire
Jan 20182412Highwire
Feb 20188900Highwire
Mar 20182500Highwire
Apr 20182510Highwire
May 20182922Highwire
Jun 20184944Highwire
Jul 20182600Highwire
Aug 20181900Highwire
Sep 20181600Highwire
Oct 20183900Highwire
Nov 20184611Highwire
Dec 20184200Highwire
Jan 20193200Highwire
Feb 20192100Highwire
Mar 20193243Highwire
Apr 20192430Highwire
May 20192902Highwire
Jun 20191200Highwire
Jul 20191510Highwire
Aug 20191500Highwire
Sep 20192611Highwire
Oct 20192500Highwire
Nov 20192101Highwire
Dec 20191901Highwire
Jan 20202200Highwire
Feb 20201300Highwire
Mar 20201801Highwire
Apr 20201700Highwire
May 20202554Highwire
Jun 20201200Highwire
Jul 2020400Highwire
Aug 20201800Highwire
Sep 20202621Highwire
Oct 20203100Highwire
Nov 20203010Highwire
Dec 20201700Highwire
Jan 20211600Highwire
Feb 20212000Highwire
Mar 20212200Highwire
Apr 20212600Highwire
May 20213520Highwire
Jun 202110510Highwire
Jul 20212510Highwire
Aug 20212400Highwire
Sep 20211010Highwire
Oct 20212500Highwire
Nov 20211900Highwire
Dec 20212800Highwire
Jan 20221400Highwire
Feb 20221700Highwire
Mar 20221311Highwire
Apr 20221400Highwire
May 20221700Highwire
Jun 20221300Highwire
Jul 2022801Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me